What is Praxis Precision Medicines, Inc.'s earnings per share (EPS)?

Praxis Precision Medicines, Inc. (PRAX) reported diluted earnings per share of -$13.48 for fiscal year 2025. This represents a -32.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Praxis Precision Medicines, Inc. (PRAX) Financials

PRAX

FY2025 annual

Revenue $0 -100.0% YoY

Net Income -$303.0M -65.6% YoY

EPS (Diluted) -$13.48 -32.0% YoY

Free Cash Flow -$249.1M -89.1% YoY

Market Cap $8.3B as of Oct 2, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 6.2x on $1.3B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PRAX SEC filings page.

Praxis Precision Medicines, Inc. (PRAX) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PRAX FY2025 2026-08-30

Praxis is a development-stage business whose dominant mechanic is financing-led research spending, not revenue-funded operations.

Between FY2024 and FY2025, research and development rose from $152.4M to $267.1M, while operating cash flow also worsened materially. That parallel movement makes the cash-conversion pattern a spending story: reported losses and cash use are closely aligned because investment in development, rather than working-capital swings, drives resource consumption.

FY2025 financing inflows reached $702.2M, far exceeding the year's operating cash outflow; this indicates that external capital, not internally generated cash, funded expansion. Total liabilities were $59.8M and debt-to-equity was 0.1x, reinforcing a low-debt posture.

Net loss widened to $303M in FY2025, yet return on assets improved to -32.3%; the apparent efficiency improvement comes from a much larger asset base absorbing losses, not from positive earnings. The reported liquidity measure was 44.6 months of annual operating outflow, a balance-sheet snapshot rather than evidence of self-funded operations.

Financial Health Signals

Financial health score not available

Praxis Precision Medicines, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

80.68

Praxis Precision Medicines, Inc. scores 80.68, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($8.3B) relative to total liabilities ($59.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Praxis Precision Medicines, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Praxis Precision Medicines, Inc. reported a net loss of $303.0M while operations used $249.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$96.9M

YoY-27.4%

QoQ+8.5%

Praxis Precision Medicines, Inc.'s EBITDA was -$96.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 27.4% from the same quarter a year earlier. Against the prior quarter it is up 8.5%.

Net Income

-$83.7M

YoY-17.7%

QoQ+9.6%

Praxis Precision Medicines, Inc. reported -$83.7M in net income in Q2 2026. This represents a decrease of 17.7% from the same quarter a year earlier. Against the prior quarter it is up 9.6%.

EPS (Diluted)

-$2.87

YoY+13.3%

QoQ+10.3%

Praxis Precision Medicines, Inc. earned -$2.87 per diluted share (EPS) in Q2 2026. This represents an increase of 13.3% from the same quarter a year earlier. Against the prior quarter it is up 10.3%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$77.8M

YoY-42.1%

QoQ+9.8%

Praxis Precision Medicines, Inc. recorded an outflow of $77.8M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 42.1% from the same quarter a year earlier. Against the prior quarter it is up 9.8%.

Cash & Debt

$474.8M

YoY+201.6%

QoQ-11.5%

5Y CAGR+22.0%

Praxis Precision Medicines, Inc. held $474.8M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

28M

YoY+32.7%

QoQ+0.1%

5Y CAGR-9.0%

Praxis Precision Medicines, Inc. had 28M shares outstanding in Q2 2026. This represents an increase of 32.7% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-6.2%

YoY+11.4pp

QoQ+0.3pp

Praxis Precision Medicines, Inc.'s ROE was -6.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 11.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$69.4M

YoY+10.2%

QoQ-11.0%

Praxis Precision Medicines, Inc. invested $69.4M in research and development in Q2 2026. This represents an increase of 10.2% from the same quarter a year earlier. Against the prior quarter it is down 11.0%.

Capital Expenditures

$245K

YoY+337.5%

QoQ+295.2%

Praxis Precision Medicines, Inc. invested $245K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 337.5% from the same quarter a year earlier. Against the prior quarter it is up 295.2%.

Share Buybacks

Not reported for Q2 2026.

PRAX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PRAX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY21DEF 14A	FY2010-K	FY1910-K
Revenue	N/A	$0-100.0%	$8.6M+249.5%	$2.4M	$0	N/A	N/A	N/A
R&D Expenses	N/A	$267.1M+75.3%	$152.4M+75.7%	$86.8M-44.0%	$155.0M+28.9%	$120.3M+167.4%	$45.0M+52.2%	$29.6M
SG&A Expenses	N/A	$59.1M+4.9%	$56.3M+33.9%	$42.1M-29.8%	$59.9M+27.3%	$47.1M+177.0%	$17.0M+172.7%	$6.2M
Operating Income	N/A	-$326.2M-63.0%	-$200.2M-58.4%	-$126.4M+41.2%	-$215.0M-28.5%	-$167.3M-170.0%	-$62.0M-73.1%	-$35.8M
EBITDA	N/A	-$326.1M-63.2%	-$199.8M-58.7%	-$125.9M+41.3%	-$214.6M-28.4%	-$167.2M-170.0%	-$61.9M-73.2%	-$35.8M
Income Tax	N/A	$471K	N/A	N/A	N/A	$0+100.0%	-$8K+90.5%	-$84K
Net Income	N/A	-$303.0M-65.6%	-$183.0M-48.8%	-$123.0M+42.5%	-$214.0M-28.1%	-$167.0M-170.1%	-$61.8M-74.1%	-$35.5M
EPS (Basic)	N/A	-$13.48-32.0%	-$10.21+45.4%	-$18.69+73.2%	-$69.65-1667.8%	-$3.94+49.9%	-$7.86	N/A
EPS (Diluted)	-$12.94	-$13.48-32.0%	-$10.21	-$18.69	-$69.65	-$3.94	-$7.86	N/A
Diluted Shares (Avg)	N/A	23M+25.7%	18M	7M	3M	42M	9M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	$0-100.0%	$0-100.0%	$0-100.0%	$7.5M+1349.1%	$302K-35.5%
R&D Expenses	$69.4M+10.2%	$78.0M+28.3%	N/A	$65.8M+57.1%	$63.0M+131.1%	$60.8M+125.3%	$56.3M+206.1%	$41.9M+142.6%
SG&A Expenses	$27.5M+110.5%	$27.9M+100.2%	N/A	$12.6M-17.7%	$13.1M+23.4%	$13.9M-9.2%	$15.1M+52.3%	$15.3M+74.9%
Operating Income	-$96.9M-27.4%	-$105.9M-41.7%	N/A	-$78.4M-37.9%	-$76.1M-102.9%	-$74.7M-78.4%	-$64.0M-130.0%	-$56.8M-122.7%
EBITDA	-$96.9M-27.4%	-$105.8M-41.7%	N/A	-$78.3M-38.1%	-$76.0M-103.4%	-$74.7M-78.8%	-$63.9M-130.8%	-$56.7M-123.3%
Net Income	-$83.7M-17.7%	-$92.6M-33.6%	N/A	-$73.9M-42.4%	-$71.1M-117.7%	-$69.3M-75.2%	-$58.7M-118.3%	-$51.9M-110.7%
EPS (Basic)	-$2.87+13.3%	-$3.20+2.7%	-$3.51-17.0%	-$3.36-22.2%	-$3.31-90.2%	-$3.29-15.8%	-$3.00-53.1%	-$2.75-1.1%
EPS (Diluted)	-$2.87+13.3%	-$3.20+2.7%	-$3.51-17.0%	-$3.36-22.2%	-$3.31-90.2%	-$3.29	-$3.00-53.1%	-$2.75
Diluted Shares (Avg)	29M+35.7%	29M+37.2%	N/A	22M+16.4%	21M+14.1%	21M	N/A	19M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

PRAX Balance Sheet

PRAX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY21DEF 14A	FY2010-K	FY1910-K
Total Assets	$937.9M+94.1%	$483.1M+449.3%	$87.9M-23.6%	$115.1M-60.7%	$292.7M-3.4%	$303.2M+535.7%	$47.7M
Current Assets	$610.9M+51.1%	$404.4M+376.4%	$84.9M-23.4%	$110.8M-61.4%	$287.4M-4.9%	$302.3M+564.5%	$45.5M
Cash & Equivalents	$357.3M+65.9%	$215.4M+164.9%	$81.3M+31.9%	$61.6M-55.6%	$138.7M-53.2%	$296.6M+561.8%	$44.8M
Short-Term Investments	$242.0M+36.6%	$177.2M	$0-100.0%	$38.9M-63.2%	$105.7M	$0	$0
Long-Term Investments	$326.8M+324.6%	$77.0M	$0	$0-100.0%	$31.5M	$0	$0
Total Liabilities	$59.8M+58.7%	$37.7M+106.0%	$18.3M-53.2%	$39.0M-6.9%	$41.9M+166.8%	$15.7M-87.8%	$128.7M
Current Liabilities	$59.8M+59.2%	$37.5M+138.4%	$15.7M-54.1%	$34.3M-10.6%	$38.4M+144.5%	$15.7M+130.6%	$6.8M
Non-Current Liabilities	$0-100.0%	$110K-95.7%	$2.5M-45.9%	$4.7M+33.6%	$3.5M	$0-100.0%	$121.9M
Total Equity	$878.1M+97.1%	$445.4M+539.4%	$69.7M-8.5%	$76.1M-69.7%	$250.8M-12.7%	$287.5M+454.9%	-$81.0M
Retained Earnings	-$1.1B-36.2%	-$836.7M-28.0%	-$653.9M-23.2%	-$530.6M-67.6%	-$316.6M-111.7%	-$149.6M-84.6%	-$81.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.4B+207.0%	$1.5B+205.0%	$937.9M+94.1%	$396.4M-4.8%	$452.8M+2.7%	$478.7M+91.2%	$483.1M+449.3%	$416.3M+290.0%
Current Assets	$771.9M+151.8%	$797.8M+139.2%	$610.9M+51.1%	$273.8M-23.9%	$306.6M-14.1%	$333.6M+57.5%	$404.4M+376.4%	$360.0M+248.5%
Cash & Equivalents	$474.8M+201.6%	$536.3M+223.9%	$357.3M+65.9%	$149.5M-11.3%	$157.4M+8.5%	$165.6M+8.9%	$215.4M+164.9%	$168.6M+66.8%
Short-Term Investments	$283.8M+97.3%	$250.5M+54.2%	$242.0M+36.6%	$117.6M-37.6%	$143.9M-30.4%	$162.4M+193.0%	$177.2M	$188.4M
Long-Term Investments	$615.3M+323.3%	$660.9M+358.9%	$326.8M+324.6%	$122.0M+125.4%	$145.4M+77.4%	$144.0M+301.5%	$77.0M	$54.1M
Total Liabilities	$49.1M+0.9%	$50.2M+27.1%	$59.8M+58.7%	$52.9M+57.4%	$48.6M+121.3%	$39.5M+90.7%	$37.7M+106.0%	$33.6M+68.2%
Current Liabilities	$49.1M+0.9%	$50.2M+27.1%	$59.8M+59.2%	$52.9M+60.9%	$48.6M+135.7%	$39.5M+110.3%	$37.5M+138.4%	$32.9M+95.7%
Non-Current Liabilities	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$110K-95.7%	$729K-77.1%
Total Equity	$1.3B+231.8%	$1.4B+221.0%	$878.1M+97.1%	$343.5M-10.2%	$404.2M-3.5%	$439.2M+91.2%	$445.4M+539.4%	$382.7M+341.1%
Retained Earnings	-$1.3B-34.7%	-$1.2B-36.0%	-$1.1B-36.2%	-$1.1B-35.1%	-$977.2M-34.6%	-$906.0M-30.7%	-$836.7M-28.0%	-$778.1M-24.1%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

PRAX Cash Flow Statement

PRAX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY21DEF 14A	FY2010-K	FY1910-K
Operating Cash Flow	-$305.1M	-$249.1M-89.0%	-$131.8M-18.6%	-$111.1M+39.9%	-$185.0M-48.6%	-$124.6M-136.7%	-$52.6M-57.5%	-$33.4M
Depreciation & Amortization	N/A	$140K-60.9%	$358K-17.1%	$432K+3.1%	$419K+130.2%	$182K+264.0%	$50K+35.1%	$37K
Stock-Based Compensation	N/A	$33.9M-17.9%	$41.4M+66.4%	$24.9M-13.1%	$28.6M+26.0%	$22.7M+335.5%	$5.2M+680.1%	$668K
Capital Expenditures	$307K	$56K	$0-100.0%	$50K-88.7%	$444K-57.7%	$1.1M	$0-100.0%	$103K
Free Cash Flow	-$305.4M	-$249.1M-89.1%	-$131.8M-18.5%	-$111.2M+40.1%	-$185.5M-47.7%	-$125.6M-138.7%	-$52.6M-57.0%	-$33.5M
Investing Cash Flow	-$611.3M	-$311.1M-25.2%	-$248.5M-738.0%	$39.0M-59.8%	$96.9M+169.0%	-$140.5M	$0+100.0%	-$103K
Financing Cash Flow	$1.2B	$702.2M+36.5%	$514.3M+459.8%	$91.9M+777.9%	$10.5M-90.3%	$107.6M-64.7%	$304.4M+404.1%	$60.4M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$77.5M-41.8%	-$86.2M-62.5%	-$76.3M-36.0%	-$65.1M-136.6%	-$54.7M-100.4%	-$53.0M-154.2%	-$56.1M-135.2%	-$27.5M-18.5%
Depreciation & Amortization	$33K-28.3%	$39K-17.0%	$28K-40.4%	$19K-79.3%	$46K-57.0%	$47K-58.0%	$47K-57.7%	$92K-15.6%
Stock-Based Compensation	$11.3M+45.5%	$17.1M+94.8%	N/A	$7.4M-40.1%	$7.8M+32.2%	$8.8M-39.3%	N/A	$12.4M+115.7%
Capital Expenditures	$245K+337.5%	$62K	$0	$0	$56K	$0	$0-100.0%	$0
Free Cash Flow	-$77.8M-42.1%	-$86.2M-62.6%	-$76.3M-36.0%	-$65.1M-136.6%	-$54.7M	-$53.0M	-$56.1M-134.7%	-$27.5M-18.5%
Investing Cash Flow	$11.0M-38.6%	-$344.3M-574.2%	-$328.4M-2907.8%	$50.4M+1.7%	$17.9M+109.1%	-$51.1M+44.0%	-$10.9M-21736.0%	$49.6M
Financing Cash Flow	$4.6M-84.0%	$609.4M+1023.0%	$612.5M+438.4%	$6.8M+370.5%	$28.6M-86.8%	$54.3M-70.3%	$113.8M+2657.3%	$1.4M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PRAX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PRAX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY21DEF 14A	FY2010-K	FY1910-K
Operating Margin	N/A	-2340.3%	-5164.4%	N/A	N/A	N/A	N/A
Net Margin	N/A	-2139.6%	-5026.6%	N/A	N/A	N/A	N/A
Return on Equity	-34.5%+6.6pp	-41.1%+135.5pp	-176.6%+104.6pp	-281.2%-214.6pp	-66.6%-45.1pp	-21.5%	N/A
Return on Assets	-32.3%+5.6pp	-37.9%+102.0pp	-139.9%+46.0pp	-185.9%-128.8pp	-57.0%-36.7pp	-20.4%+54.1pp	-74.5%
Current Ratio	10.22-0.5x	10.77+5.4x	5.39+2.2x	3.23-4.3x	7.48-11.8x	19.23+12.6x	6.67
Debt-to-Equity	0.070.0x	0.08-0.2x	0.26-0.3x	0.51+0.3x	0.17+0.1x	0.05	N/A
Asset Turnover	0.000.0x	0.020.0x	0.030.0x	0.00	N/A	N/A	N/A
FCF Margin	N/A	-1540.5%	-4543.8%	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	-857.0%	-18819.5%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	-786.3%	-17188.7%
Return on Equity	-6.2%+11.4pp	-6.6%+9.2pp	N/A	-21.5%-8.0pp	-17.6%-9.8pp	-15.8%+1.4pp	-13.2%+25.4pp	-13.6%+14.8pp
Return on Assets	-6.0%+9.7pp	-6.3%+8.1pp	N/A	-18.6%-6.2pp	-15.7%-8.3pp	-14.5%+1.3pp	-12.2%+18.4pp	-12.5%+10.6pp
Current Ratio	15.73+9.4x	15.88+7.4x	10.22-0.5x	5.18-5.8x	6.31-11.0x	8.44-2.8x	10.77+5.4x	10.96+4.8x
Debt-to-Equity	0.04-0.1x	0.04-0.1x	0.070.0x	0.15+0.1x	0.12+0.1x	0.090.0x	0.08-0.2x	0.09-0.1x
Asset Turnover	N/A	N/A	N/A	0.000.0x	0.000.0x	0.000.0x	0.020.0x	0.000.0x
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-752.0%	-9106.0%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Praxis Precision Medicines, Inc. PRAX	FY2025	$0	-$303.0M	N/A	$8.3B	—
Anavex Life Sciences AVXL	FY2025	N/A	-$46.4M	N/A	$175.2M	—
EyePoint, Inc. EYPT	FY2025	$31.4M	-$232.0M	N/A	$278.5M	46/100
Nektar Therapeutics NKTR	FY2025	$55.2M	-$164.0M	N/A	$1.6B	56/100
Sana Biotechnology, Inc. SANA	FY2025	N/A	-$244.2M	N/A	$865.2M	—
Zenas BioPharma, Inc. ZBIO	FY2025	$10.0M	-$377.7M	N/A	$1.8B	36/100

Where Praxis Precision Medicines, Inc. Ranks

Frequently Asked Questions

What is Praxis Precision Medicines, Inc.'s annual revenue?

Praxis Precision Medicines, Inc. (PRAX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Praxis Precision Medicines, Inc.'s revenue growing?

Praxis Precision Medicines, Inc. (PRAX) revenue declined by 100.0% year-over-year, from $8.6M to $0 in fiscal year 2025.

Is Praxis Precision Medicines, Inc. profitable?

No, Praxis Precision Medicines, Inc. (PRAX) reported a net income of -$303.0M in fiscal year 2025.

What is Praxis Precision Medicines, Inc.'s EBITDA?

Praxis Precision Medicines, Inc. (PRAX) had EBITDA of -$326.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Praxis Precision Medicines, Inc.'s return on equity (ROE)?

Praxis Precision Medicines, Inc. (PRAX) has a return on equity of -34.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Praxis Precision Medicines, Inc.'s free cash flow?

Praxis Precision Medicines, Inc. (PRAX) recorded an outflow of $249.1M in free cash flow during fiscal year 2025. This represents a -89.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Praxis Precision Medicines, Inc.'s operating cash flow?

Praxis Precision Medicines, Inc. (PRAX) recorded an outflow of $249.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Praxis Precision Medicines, Inc.'s total assets?

Praxis Precision Medicines, Inc. (PRAX) had $937.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Praxis Precision Medicines, Inc.'s capital expenditures?

Praxis Precision Medicines, Inc. (PRAX) invested $56K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Praxis Precision Medicines, Inc. spend on research and development?

Praxis Precision Medicines, Inc. (PRAX) invested $267.1M in research and development during fiscal year 2025.

How many shares does Praxis Precision Medicines, Inc. have outstanding?

Praxis Precision Medicines, Inc. (PRAX) had 28M shares outstanding as of fiscal year 2025.

What is Praxis Precision Medicines, Inc.'s current ratio?

Praxis Precision Medicines, Inc. (PRAX) had a current ratio of 10.22 as of fiscal year 2025, which is generally considered healthy.

What is Praxis Precision Medicines, Inc.'s debt-to-equity ratio?

Praxis Precision Medicines, Inc. (PRAX) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Praxis Precision Medicines, Inc.'s return on assets (ROA)?

Praxis Precision Medicines, Inc. (PRAX) had a return on assets of -32.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Praxis Precision Medicines, Inc.'s P/E ratio?

Praxis Precision Medicines, Inc. (PRAX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $8.3B as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Praxis Precision Medicines, Inc.'s price-to-sales ratio?

Praxis Precision Medicines, Inc. (PRAX) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $8.3B as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Praxis Precision Medicines, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Praxis Precision Medicines, Inc. (PRAX) held $926.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $249.1M over that year. Dividing the one by the other, the reported balance equals about 45 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Praxis Precision Medicines, Inc.'s Altman Z-Score?

Praxis Precision Medicines, Inc. (PRAX) has an Altman Z-Score of 80.68, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Praxis Precision Medicines, Inc.'s Piotroski F-Score?

Praxis Precision Medicines, Inc. (PRAX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Praxis Precision Medicines, Inc.'s earnings high quality?

Praxis Precision Medicines, Inc. (PRAX) reported a net loss of $303.0M while operations used $249.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.